Phase II Study of Gemcitabine Plus Erlotinib Versus Erlotinib Plus Gemcitabine Plus Oxaliplatin, in Patients With Locally Advanced or Metastic Pancreatic Cancer
Phase of Trial: Phase II
Latest Information Update: 14 Feb 2013
At a glance
- Drugs Erlotinib (Primary) ; Gemcitabine (Primary) ; Oxaliplatin
- Indications Pancreatic cancer
- Focus Therapeutic Use
- 20 May 2011 Status changed from recruiting to discontinued as reported by ClinicalTrials.gov.
- 20 May 2011 Planned end date changed from 1 Feb 2011 to 1 Mar 2011 as reported by ClinicalTrials.gov.
- 11 Oct 2010 Planned end date changed from 1 Dec 2010 to 1 Feb 2011 as reported by ClinicalTrials.gov.